Get access

Interventions for preventing the progression of autosomal dominant polycystic kidney disease

  • Protocol
  • Intervention

Authors

  • Davide Bolignano,

    Corresponding author
    1. CNR- IBIM Italian National Council of Research, Reggio Calabria, Italy
    • Davide Bolignano, CNR- IBIM Italian National Council of Research, Via Vallone Petrara c/o Ospedali Riuniti, Reggio Calabria, 89100, Italy. davide.bolignano@gmail.com.

    Search for more papers by this author
  • Marinella Ruospo,

    1. Mario Negri Sud Consortium, Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Chieti, Italy
    Search for more papers by this author
  • Carmine Zoccali,

    1. Ospedali Riuniti, Nephrology, Hypertension & Renal Transplantation Unit, CNR-IBIM Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    Search for more papers by this author
  • Jonathan C Craig,

    1. The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    Search for more papers by this author
  • Giovanni FM Strippoli

    1. The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    3. University of Bari, Department of Emergency and Organ Transplantation, Bari, Italy
    4. Mario Negri Sud Consortium, Department of Clinical Pharmacology and Epidemiology, Santa Maria Imbaro, Italy
    5. Diaverum, Medical-Scientific Office, Lund, Sweden
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  • To evaluate the effects of interventions directed at preventing the progression of ADPKD on kidney function, such as GFR, serum creatinine (SCr), doubling of SCr concentration, ESKD, need for RRT, proteinuria or urinary albumin excretion.

  • To evaluate the effects of those interventions on total kidney volume, parenchymal volume, and kidney cyst volume.

  • To evaluate the effects of those interventions on patient-centred endpoints such as incidence of (fatal and non-fatal) cardiovascular events, sudden death, all-cause mortality, hospitalisations, blood pressure (BP) control, quality of life, and kidney pain.

  • To evaluate general and specific adverse effects related to those interventions such as dizziness, diarrhoea, abdominal cramps and nausea (all treatments); hypernatraemia, thirst, dry mouth, and headache (V2R-antagonists); angioedema and infections (mTOR inhibitors); alopecia (somatostatin agonists); and hyperkalaemia (ACEi and ARBs).